Dell'OmoR,SemeraroF,BamonteG,CifarielloF,RomanoMR,CostagliolaC, 2013.Vitreous mediators in retinal hypoxic diseases,Mediators Inflamm 16 -
GoldbergRB, 2009.Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications,J Clin Endocrinol Metab 94 3171 -82
AdamisAP, 2002.Is diabetic retinopathy an inflammatory disease?,Br J Ophthalmol 86 363 -5
1991.Effects of aspirin treatment on diabetic retinopathy,ETDRS report number 8. Ophthalmology 98 757 -77
FangYH,ZhangJP,ZhouSX,ZhengJF,YuYW,YanSG, 2005.Clinical analysis of serum endothelin in type 2 diabetic patients with vascular complications,Di Yi Jun Yi Da Xue Xue Bao 25 1007 -8
MostafaMS,SamyN,AfifyM,HashemM,AzebA, 2005.Evaluation of plasma endorthelin-1 and serum inflammatory markers in patients with diabetic retinopathy,J Med Sci 5 35 -42
HansenJ,RinnovA,Krogh-MadsenR,FischerCP,AndreasenAS,BergRM, .Plasma follistatin is elevated in patients with, -
FanX,WuQ,LiY,HaoY,NingN,KangZ, 2004.Association of polymorphisms in the vascular endothelial growth factor gene and its serum levels with diabetic retinopathy in Chinese patients with type 2 diabetes: a cross-sectional study,Chin Med J (Engl) 127 651 -7
MahdyRA,NadaWM,HadhoudKM,El-TarhonySA, 2010.The role of vascular endothelial growth factor in the progression of diabetic vascular complications,Eye (Lond.) 24 1576 -84
OzturkBT,BozkurtB,KerimogluH,OkkaM,KamisU,GunduzK., 2009.Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness,Mol Vis 15 1906 -14
CavusogluAC,BilgiliS,AlalufA,DoganA,YilmazF,AslancaD, 2007.Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy,Ann Ophthalm 39 205 -8
HuangH,HeJ,JohnsonD,WeiY,LiuY,WangS, 2015.Deletion of placental growth factor prevents diabetic retinopathy and is associated with akt activation and HIF1- VEGF pathway inhibition,Diabetes 64 200 -12
LiW,SalmonRM,JiangH, 2016.Regulation of the ALK1 ligands, BMP9 and BMP10,Biochem Soc Trans 44 1135 -41
CantonA,BurgosR,HernandezC,MateoC,SeguraR,MesaJ,SimoR, 2000.Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy,Br J Ophthalmol 84 732 -5
KonyaH,MiuchiM,SataniK,MatsutaniS,TsunodaT,YanoY, 2014.Hepatocyte growth factor, a biomarker of macro-angiopathy in diabetes mellitus,World J Diabetes 15 678 -88
ChengX,ZhuB,JiangF,Fan H. Serum, 2011.21 levels in type 2 diabetic patients,Endocr Res 36 142 -48
LinY,XiaoY,ZhuH,XuQ,QiL,WangY, 2014.Serum fibroblast growth factor 21 levels are correlated with severity of diabetic retinopathy,J Diabetes Res 929756 -
HaffnerS,SternM,MiettinenH,WeiM,GingerichR, 1996.Leptin concentrations in diabetic and nondiabetic MexicanAmericans,Diabetes 45 822 -4
MohammadzadehG,ZarghamiN., 2013.Serum leptin level is reduced in non-obese subjects with type 2 diabetes,Int J Endocrinol Metab 11 3 -10
SunQ.,Van DamR,MeigsJ,FrancoO,MantzorosC, 2010.Leptin and soluble leptin receptor levels in plasma and risk of type 2 diabetes in U.S. women: a prospective study,Diabetes 59 611 -8
WelshP,MurrayH,BuckleyB, 2009.Leptin predicts diabetes but not cardiovascular disease: results from a large prospective study in an elderly population,Diabetes Care 32 308 -10
SheikhMH, 2017.The determinants of leptin levels in diabetic and nondiabetic Saudi males,Int J Endocrinol 3506871 -
RasulS,ReiterMH,IlhanA,LampichlerK,WagnerL,KautzkyWilleA, 2011.Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-scetional study,Cardiovasc Diabetol 10 55 -
LiL,QianL,YuZQ, 2015.Serum angiopoietin-2 is associated with angiopathy in type 2 diabetes mellitus,J Diabetes Complications 29 568 -571
PatelB,HiscottP,CharterisD,MatherJ,McLeodD,BoultonM. Retinal, 1994.and preretinal localisation of epidermal growth factor, transforming growth factor alpha, and their receptor in proliferative diabetic retinopathy,Br J Ophthalmol 78 714 -8